Found 6 results
Filters: Author is L.J. Yang  [Clear All Filters]
M. L. Lai, Yang, L. J., Zhu, X. H., and Li, M., A novel mutation of the DSRAD gene in a Chinese family with dyschromatosis symmetrica hereditaria, vol. 11, pp. 1731-1737, 2012.
Alfadley A, Al AA, Hainau B, Pedersen KT, et al. (2000). Reticulate acropigmentation of Dohi: a case report of autosomal recessive inheritance. J. Am. Acad. Dermatol. 43: 113-117. PMid:10863235   Cho DS, Yang W, Lee JT, Shiekhattar R, et al. (2003). Requirement of dimerization for RNA editing activity of adenosine deaminases acting on RNA. J. Biol. Chem. 278: 17093-17102. PMid:12618436   Liu Q, Jiang L, Liu WL, Kang XJ, et al. (2006). Two novel mutations and evidence for haploinsufficiency of the ADAR gene in dyschromatosis symmetrica hereditaria. Br. J. Dermatol. 154: 636-642. PMid:16536805   Miyamura Y, Suzuki T, Kono M, Inagaki K, et al. (2003). Mutations of the RNA-specific adenosine deaminase gene (DSRAD) are involved in dyschromatosis symmetrica hereditaria. Am. J. Hum. Genet. 73: 693-699. PMid:12916015 PMCid:1180697   Murata I, Hayashi M, Hozumi Y, Fujii K, et al. (2010). Mutation analyses of patients with dyschromatosis symmetrica hereditaria: five novel mutations of the ADAR1 gene. J. Dermatol. Sci. 58: 218-220. PMid:20439151   O'Connell MA, Krause S, Higuchi M, Hsuan JJ, et al. (1995). Cloning of cDNAs encoding mammalian double-stranded RNA-specific adenosine deaminase. Mol. Cell Biol. 15: 1389-1397. PMid:7862132 PMCid:230363   Oiso N, Murata I, Hayashi M, Amatsu A, et al. (2011). Dermoscopic features in a case of dyschromatosis symmetrica hereditaria. J. Dermatol. 38: 91-93. PMid:21175763   Ostlere LS, Ratnavel RC, Lawlor F, Black MM, et al. (1995). Reticulate acropigmentation of Dohi. Clin. Exp. Dermatol. 20: 477-479. PMid:8857341   Oyama M, Shimizu H, Ohata Y, Tajima S, et al. (1999). Dyschromatosis symmetrica hereditaria (reticulate acropigmentation of Dohi): report of a Japanese family with the condition and a literature review of 185 cases. Br. J. Dermatol. 140: 491-496. PMid:10233273   Rueter SM, Dawson TR and Emeson RB (1999). Regulation of alternative splicing by RNA editing. Nature 399: 75-80. PMid:10331393   Schade M, Turner CJ, Kuhne R, Schmieder P, et al. (1999). The solution structure of the Zalpha domain of the human RNA editing enzyme ADAR1 reveals a prepositioned binding surface for Z-DNA. Proc. Natl. Acad. Sci. U. S. A. 96: 12465-12470. PMid:10535945 PMCid:22950   Sun XK, Xu AE, Chen JF and Tang X (2005). The double-RNA-specific adenosine deaminase (DSRAD) gene in dyschromatosis symmetrica hereditaria patients: two novel mutations and one previously described. Br. J. Dermatol. 153: 342-345. PMid:16086746   Suzuki N, Suzuki T, Inagaki K, Ito S, et al. (2005). Mutation analysis of the ADAR1 gene in dyschromatosis symmetrica hereditaria and genetic differentiation from both dyschromatosis universalis hereditaria and acropigmentatio reticularis. J. Invest. Dermatol. 124: 1186-1192. PMid:15955093   Urabe K and Hori Y (1997). Dyschromatosis. Semin. Cutan. Med. Surg. 16: 81-85.   Wagner RW, Smith JE, Cooperman BS and Nishikura K (1989). A double-stranded RNA unwinding activity introduces structural alterations by means of adenosine to inosine conversions in mammalian cells and Xenopus eggs. Proc. Natl. Acad. Sci. U. S. A. 86: 2647-2651. PMid:2704740 PMCid:286974   Zhang XJ, Gao M, Li M, Li M, et al. (2003). Identification of a locus for dyschromatosis symmetrica hereditaria at chromosome 1q11-1q21. J. Invest. Dermatol. 120: 776-780. PMid:12713580
B. Jiang, Zhu, Z. Z., Liu, F., Yang, L. J., Zhang, W. Y., Yuan, H. H., Wang, J. G., Hu, X. H., and Huang, G., STAT3 gene polymorphisms and susceptibility to non-small cell lung cancer, vol. 10, pp. 1856-1865, 2011.
Abdulghani J, Gu L, Dagvadorj A, Lutz J, et al. (2008). Stat3 promotes metastatic progression of prostate cancer. Am. J. Pathol. 172: 1717-1728. PMid:18483213    PMCid:2408430 Barrett JC, Fry B, Maller J and Daly MJ (2005). Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 21: 263-265. PMid:15297300 Barrett JC, Hansoul S, Nicolae DL, Cho JH, et al. (2008). Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat. Genet. 40: 955-962. PMid:18587394    PMCid:2574810 Bollrath J, Phesse TJ, von Burstin VA, Putoczki T, et al. (2009). gp130-mediated Stat3 activation in enterocytes regulates cell survival and cell-cycle progression during colitis-associated tumorigenesis. Cancer Cell 15: 91-102. PMid:19185844 Bowman T, Garcia R, Turkson J and Jove R (2000). STATs in oncogenesis. Oncogene 19: 2474-2488. PMid:10851046 Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, et al. (1999). Stat3 as an oncogene. Cell 98: 295-303. Darnell JE (2005). Validating Stat3 in cancer therapy. Nat. Med. 11: 595-596. PMid:15937466 Dauer DJ, Ferraro B, Song L, Yu B, et al. (2005). Stat3 regulates genes common to both wound healing and cancer. Oncogene 24: 3397-3408. PMid:15735721 Ferguson LR, Han DY, Fraser AG, Huebner C, et al. (2010). Genetic factors in chronic inflammation: single nucleotide polymorphisms in the STAT-JAK pathway, susceptibility to DNA damage and Crohn’s disease in a New Zealand population. Mutat. Res. 690: 108-115. PMid:20109474 Fletcher S, Drewry JA, Shahani VM, Page BD, et al. (2009). Molecular disruption of oncogenic signal transducer and activator of transcription 3 (STAT3) protein. Biochem. Cell Biol. 87: 825-833. PMid:19935868 Grivennikov SI and Karin M (2010). Dangerous liaisons: STAT3 and NF-kappaB collaboration and crosstalk in cancer. Cytokine Growth Factor Rev. 21: 11-19. Horinaga M, Okita H, Nakashima J, Kanao K, et al. (2005). Clinical and pathologic significance of activation of signal transducer and activator of transcription 3 in prostate cancer. Urology 66: 671-675. PMid:16140113 Hsieh FC, Cheng G and Lin J (2005). Evaluation of potential Stat3-regulated genes in human breast cancer. Biochem. Biophys. Res. Commun. 335: 292-299. PMid:16081048 Hsu HS, Huang PI, Chang YL, Tzao C, et al. (2011). Cucurbitacin i inhibits tumorigenic ability and enhances radiochemosensitivity in nonsmall cell lung cancer-derived CD133-positive cells. Cancer 117: 2970-2985. PMid:21225866 Ito N, Eto M, Nakamura E, Takahashi A, et al. (2007). STAT3 polymorphism predicts interferon-alfa response in patients with metastatic renal cell carcinoma. J. Clin. Oncol. 25: 2785-2791. PMid:17602083 Jing N, Zhu Q, Yuan P, Li Y, et al. (2006). Targeting signal transducer and activator of transcription 3 with G-quartet oligonucleotides: a potential novel therapy for head and neck cancer. Mol. Cancer Ther. 5: 279-286. PMid:16505101 Karin M (2006). Nuclear factor-kappaB in cancer development and progression. Nature 441: 431-436. PMid:16724054 Kreil S, Waghorn K, Ernst T, Chase A, et al. (2010). A polymorphism associated with STAT3 expression and response of chronic myeloid leukemia to interferon alpha. Haematologica 95: 148-152. PMid:20065083    PMCid:2805737 Lai SY and Johnson FM (2010). Defining the role of the JAK-STAT pathway in head and neck and thoracic malignancies: implications for future therapeutic approaches. Drug Resist. Updat. 13: 67-78. PMid:20471303 Lin Q, Lai R, Chirieac LR, Li C, et al. (2005). Constitutive activation of JAK3/STAT3 in colon carcinoma tumors and cell lines: inhibition of JAK3/STAT3 signaling induces apoptosis and cell cycle arrest of colon carcinoma cells. Am. J. Pathol. 167: 969-980. Parkin DM, Bray F, Ferlay J and Pisani P (2005). Global cancer statistics, 2002. CA Cancer J. Clin. 55: 74-108. Sansone P, Storci G, Tavolari S, Guarnieri T, et al. (2007). IL-6 triggers malignant features in mammospheres from human ductal breast carcinoma and normal mammary gland. J. Clin. Invest. 117: 3988-4002. PMid:18060036    PMCid:2096439 Scagliotti GV, Longo M and Novello S (2009). Nonsmall cell lung cancer in never smokers. Curr. Opin. Oncol. 21: 99-104. PMid:19532009 Shields PG (2002). Molecular epidemiology of smoking and lung cancer. Oncogene 21: 6870-6876. PMid:12362269 Siddiquee K, Zhang S, Guida WC, Blaskovich MA, et al. (2007a). Selective chemical probe inhibitor of Stat3, identified through structure-based virtual screening, induces antitumor activity. Proc. Natl. Acad. Sci. U. S. A. 104: 7391-7396. PMid:17463090    PMCid:1863497 Siddiquee KA, Gunning PT, Glenn M, Katt WP, et al. (2007b). An oxazole-based small-molecule Stat3 inhibitor modulates Stat3 stability and processing and induces antitumor cell effects. ACS Chem. Biol. 2: 787-798. PMid:18154266 Stephens M, Smith NJ and Donnelly P (2001). A new statistical method for haplotype reconstruction from population data. Am. J. Hum. Genet. 68: 978-989. PMid:11254454 Turkson J (2004). STAT proteins as novel targets for cancer drug discovery. Expert. Opin. Ther. Targets. 8: 409-422. PMid:15469392 Vaclavicek A, Bermejo JL, Schmutzler RK, Sutter C, et al. (2007). Polymorphisms in the Janus kinase 2 (JAK)/signal transducer and activator of transcription (STAT) genes: putative association of the STAT gene region with familial breast cancer. Endocr. Relat. Cancer 14: 267-277. PMid:17639043 Weerasinghe P, Garcia GE, Zhu Q, Yuan P, et al. (2007). Inhibition of Stat3 activation and tumor growth suppression of non-small cell lung cancer by G-quartet oligonucleotides. Int. J. Oncol. 31: 129-136. PMid:17549413 Yang L, Parkin DM, Li LD, Chen YD, et al. (2004). Estimation and projection of the national profile of cancer mortality in China: 1991-2005. Br. J. Cancer 90: 2157-2166. PMid:15150609    PMCid:2409509 Yin W, Cheepala S, Roberts JN, Syson-Chan K, et al. (2006). Active Stat3 is required for survival of human squamous cell carcinoma cells in serum-free conditions. Mol. Cancer 5: 15. PMid:16603078    PMCid:1502137 Yin ZJ, Jin FG, Liu TG, Fu EQ, et al. (2010). Overexpression of STAT3 potentiates growth, survival, and radioresistance of non-small-cell lung cancer (NSCLC) cells. J. Surg. Res. Doi: 10.1016/j.jss.2010.03.053. PMid:20605584 Yu H and Jove R (2004). The STATs of cancer - new molecular targets come of age. Nat. Rev. Cancer 4: 97-105. PMid:14964307 Yu H, Pardoll D and Jove R (2009). STATs in cancer inflammation and immunity: a leading role for STAT3. Nat. Rev. Cancer 9: 798-809. PMid:19851315